Global ChordomaDisease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline,VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy,Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals,Clinics, Oncology Centers, and Others), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa), is expected to bevalued at US$ 5,296.31 million in 2020and is expected to exhibit a CAGR of 6.7% over the forecast period (2019-2027),as highlighted in a new report published by Coherent Market Insights.
Major players operating in thechordoma disease therapeutics market, research organizations, and non-profitorganizations are collaborating to enhance their research and developmentactivities, in order to develop advanced treatment for chordoma, which isexpected to boost the market growth over the forecast period. For instance, inJune 2019, The Cancer Research Institute (CRI) and Chordoma Foundation enteredinto a research partnership to advance treatment options for chordoma. Throughthis partnership, both the organizations will fund researches that have thepotential to bring the benefits of immunotherapy to patients with chordoma.
Global Chordoma DiseaseTherapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
Due to the COVID-19 outbreak, allthe major events held by the National Brain Tumor Society (NBTS) scheduled inthe month of March, April and May, have been moved to virtual platforms toensure the well-being of all the patients as well as healthcare providers.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3979
The clinical trials associatedwith brain tumors are being conducted with certain safety measures taken by thehealthcare facilities which include
The healthcare providers areconducting patient consents through phone or video conferences.
The patients receive a phone callfor the screening of COVID-19 symptoms before the scheduled in-person visits
The assessments of the studiesare being done in single outpatient areas.
Browse 27 Market Data Tables and26 Figures spread through 201 Pages and in-depth TOC on “Chordoma DiseaseTherapeutics Market”- Global Forecast to 2027, by Drug Class (Antimetabolites,Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type(Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User(Hospitals, Clinics, Oncology Centers, and Others), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa).
Key players operating in themarket are focused on various inorganic growth strategies such as partnershipsand agreements, in order to expand their product offerings in the market. Forinstance, in May 2018, mAbxience, a company specialized in monoclonal antibodybiosimilars, and Amneal Pharmaceuticals, Inc. signed an exclusive licensing andsupply agreement for mAbxience´s bevacizumab, a biosimilar candidate forAvastin. Through this agreement, Amneal Pharmaceuticals, Inc. gained the rightsto commercialize mAbxience´s bevacizumab in the U.S.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/chordoma-disease-therapeutics-market-3979
Key Takeaways of the GlobalChordoma Disease Therapeutics Market:
The global chordoma diseasetherapeutics market is expected to exhibit a CAGR of 6.7% over the forecastperiod, owing to increased product launches and approvals, and increasingprevalence of chordoma. For instance, in September 2016, the Bone CancerResearch Trust estimated that around 35 people are diagnosed with chordomaevery year, in the U.K. and Ireland.
Among drug class, VEGFR inhibitorsegment held the largest market share in 2019, owing to increasing launches ofnew drugs in the market. For instance, in December 2019, Daiichi SankyoCompany, Limited, a pharmaceutical company, launched bevacizumab BS forintravenous drip infusions in Japan.
Among treatment type, targetedtherapy segment held largest market share in 2019, owing to increased launchesand approvals generic drugs for chordoma treatment. For instance, in May 2019,Teva Pharmaceutical Industries Ltd. launched the generic version of Tarceva(erlotinib) tablets in the U.S.
Companies operating in the globalchordoma disease therapeutics market include GlaxoSmithKline Plc, BavarianNordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck &Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc.,Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr.Reddy’s Laboratories Ltd., and Mylan N.V.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3979
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
